Our latest
News
Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026
Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis
Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation
Mauna Kea Technologies Announces Nomination of 3 New Directors
Publication of the 2025 Annual Financial Report
Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026
Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025
Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth
Mauna Kea Technologies Updates Its Financial Calendar
Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plenary Session at DDW 2026
Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom
Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes
No results found.